183170-69-6

Basic information

• Product Name: tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate;4-(1-Hydroxy-ethyl)-piperidine-1-carboxylic acid tert-butyl ester;1-Boc-4-(1-hydroxyethyl)-piperidine;1-tert-Butoxycarbonyl-4-(1-hydroxyethyl)piperidine;1,1-Dimethylethyl 4-(1-hydroxyethyl)-1-piperidinecarboxylate
• CAS NO: 183170-69-6
• Molecular Formula: C₁₂H₂₃NO₃
• Molecular Weight: 229.31592
• Mol File: 183170-69-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate(183170-69-6)
• EPA Substance Registry System: tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate(183170-69-6)

Safety Data

• Hazardous Substances Data: 183170-69-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its potential role in enhancing the properties of drug molecules, such as solubility and bioavailability.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate is utilized as a building block for the creation of complex organic compounds, leveraging its unique structural features and reactivity.
Used in Drug Formulation:
tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate is employed in drug formulation to improve the hydrophilic properties of drug molecules, potentially enhancing their solubility and absorption in biological systems.
Used in Chemical Industry:
Tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate is used as a versatile compound in various chemical processes, taking advantage of its stability and reactivity profile for the development of new materials and products.

Upstream product

• 175213-46-4 1-t-Butoxycarbonyl-4-(methoxycarbonylmethyl)piperidine 
• 6457-48-3 4-(1-hydroxyethyl)piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 206989-61-9 4-acetyl-1-(t-butoxycarbonyl)piperidine 
• 75-16-1 methylmagnesium bromide 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 498-94-2 isonipecotic acid 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 1032825-55-0 tert-butyl 4-(1-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate 
• 1138331-69-7 tert-butyl 4-(1-methyl-1-{[3-(trifluoromethyl)phenyl]sulfonyl}ethyl)piperidine-1-carboxylate 
• 1138327-98-6 tert-butyl 4-(1-{[3-(trifluoromethyl)phenyl]sulfonyl}ethyl)piperidine-1-carboxylate 
• 1138331-68-6 tert-butyl 4-(1-((3-(trifluoromethyl)phenyl)thio)ethyl)piperidine-1-carboxylate 
• 1314530-71-6 N-(4-bromomethyl-5'-chloro-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl)-3-chloro-benzamide 
• 1314530-70-5 3-chloro-N-[5'-chloro-4-(1-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl]-benzamide 
• 1314528-14-7 C₂₄H₃₀Cl₂N₄O 
• 6457-48-3 4-(1-hydroxyethyl)piperidine 
• 152903-08-7 1-Phenethyl-4-[(3-phenyl-2-propynyloxy)-ethyl] piperidine, hydrochloride salt 

Relevant articles and documents

ATF6 MODULATORS AND USES THEREOF

Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))

OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY

The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

A group of protein methylase EZH2 method for the synthesis of inhibitor intermediates (by machine translation)

The invention relates to a group of protein methylase EZH2 inhibitors of synthesis method of intermediate I, this method, in order to compound 1 as raw materials, after reduction, sulfonylation, substituted and hydrolysis to obtain compound I, the reaction of simple operation, after treatment is convenient, is not required to be purified, high total yield, environment-friendly, is simple and easy to obtain reaction materials, suitable for industrial production. (by machine translation)

GPR119 Agonists

GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1 to R3, A, B, X, and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

A series of substituted aryl sulfone derivatives represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, calcium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, diabetic neuropathy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, sleep disorder, bipolar disorder and stroke, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.

4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

Heterocyclic compounds, their production and use

A novel compound of the formula: wherein A is a condensed pyrimidinone or condensed pyridazinone ring; Ar1 and Ar2 are independently a ring; Z is a divalent group, or a salt thereof which have an excellent antitumor activity.